集成蛋白调节疗法可以防止纤维化和自身免疫在老鼠模型的硬化皮质
Elizabeth E Gerber1, Elena M Gallo, Stefani C Fontana
1McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
Nature
|October 11, 2013
概括
纤维素-1中的突变通过改变细胞矩阵相互作用导致皮肤纤维化. 在硬皮综合征的小鼠模型中,整合素调节疗法和TGF-β对抗作用逆转了纤维化和炎症.
科学领域:
- 皮肤病学 皮肤病学
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- 系统性硬化症 (SSc) 是一种纤维性疾病,病因不明.
- 皮肤硬综合征 (SSS) 是一种由纤维素-1突变引起的孟德尔病.
- SSS突变影响纤维素-1中的Arg-Gly-Asp (RGD) 基因,对细胞矩阵相互作用至关重要.
研究的目的:
- 研究由改变的细胞矩阵相互作用引起的皮肤纤维化病原性.
- 确定纤维素-1突变是否可以在小鼠模型中重复SSc类表型.
- 探索纤维化皮肤疾病的潜在治疗策略.
主要方法:
- 产生了与SSS类似的纤维素-1突变的小鼠线.
- 在突变小鼠中评估了皮肤纤维化,免疫细胞透和自身抗体的产生.
- 评估了整合素调节疗法和TGF-β对抗性的疗效.
主要成果:
- 纤维素-1突变诱导了小鼠的侵袭性皮肤纤维化.
- 突变小鼠表现出炎症细胞透和自身抗体的产生.
- 集成蛋白调节疗法和TGF-β对抗作用可以预防和逆转纤维化和炎症.
结论:
- 改变的细胞矩阵相互作用足以驱动炎症和纤维化过程.
- 整蛋白通路和TGF-β信号传递是纤维化皮肤疾病的关键治疗点.
- 这项研究为研究纤维化皮肤疾病提供了一个新的动物模型.
更多相关视频
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
7.9K
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
631
相关概念视频
Intracellular Signaling Affects Focal Adhesions
2.8K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
